MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$23.72

Market cap

$1.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$2.01B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
Myriad Genetics's revenue has increased by 2.6% QoQ
The debt has soared by 57% YoY and by 6% from the previous quarter
The company's net income fell by 45% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/
Peers: BIO EXAS BIOC BMRN

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
81.22M
Market cap
$1.93B
Enterprise value
$2.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.17
Price to sales (P/S)
2.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.97
Earnings
Revenue
$678.4M
EBIT
-$137.4M
EBITDA
-$73M
Free cash flow
-$151.6M
Per share
EPS
-$1.39
Free cash flow per share
-$1.88
Book value per share
$10.93
Revenue per share
$8.42
TBVPS
$6.6
Balance sheet
Total assets
$1.2B
Total liabilities
$312.9M
Debt
$145M
Equity
$885.8M
Working capital
$137.4M
Liquidity
Debt to equity
0.16
Current ratio
2
Quick ratio
1.58
Net debt/EBITDA
-1.21
Margins
EBITDA margin
-10.8%
Gross margin
70.2%
Net margin
-16.5%
Operating margin
-20.7%
Efficiency
Return on assets
-9.2%
Return on equity
-12.1%
Return on invested capital
-30%
Return on capital employed
-12.9%
Return on sales
-20.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
0.38%
1 week
2.77%
1 month
27.94%
1 year
-6.32%
YTD
63.47%
QTD
63.47%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$678.4M
Gross profit
$476.4M
Operating income
-$140.6M
Net income
-$112M
Gross margin
70.2%
Net margin
-16.5%
The company's net income fell by 45% QoQ
The net margin has contracted by 41% from the previous quarter
The operating income rose by 26% YoY but it fell by 7% QoQ
The company's operating margin rose by 25% YoY but it fell by 4% QoQ

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
2.17
P/S
2.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.97
The EPS has contracted by 43% from the previous quarter
MYGN's price to book (P/B) is 28% higher than its last 4 quarters average of 1.7 and 9% higher than its 5-year quarterly average of 2.0
The company's equity fell by 8% YoY and by 3.4% QoQ
The P/S is 23% higher than the last 4 quarters average of 2.3 and 4.4% higher than the 5-year quarterly average of 2.7
Myriad Genetics's revenue has increased by 2.6% QoQ

Efficiency

How efficient is Myriad Genetics business performance
The ROS has plunged by 178% YoY and by 4.1% from the previous quarter
The return on invested capital has dropped by 116% year-on-year but it has grown by 3.8% since the previous quarter
MYGN's return on equity is down by 48% since the previous quarter
Myriad Genetics's return on assets has decreased by 48% QoQ

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
The quick ratio has declined by 31% since the previous quarter and by 25% year-on-year
Myriad Genetics's current ratio has decreased by 27% from the previous quarter and by 16% YoY
The debt is 84% less than the equity
The debt to equity has soared by 60% year-on-year and by 7% since the previous quarter
The debt has soared by 57% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.